Susquehanna International Group, LLP Intellia Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$19.72 - $27.36 $17,748 - $24,624	-900 Reduced 0.23%	393,100 $8.08 Million
Q2 2024 Aug 15, 2024	BUY	$20.02 - $27.22 $2.84 Million - $3.87 Million	142,000 Added 56.35%	394,000 $8.82 Million
Q1 2024 May 07, 2024	SELL	$23.82 - $32.8 $1.93 Million - $2.65 Million	-80,900 Reduced 24.3%	252,000 $6.93 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $5.43 Million - $7.59 Million	234,600 Added 238.66%	332,900 $10.2 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $5.74 Million - $8.31 Million	-181,600 Reduced 64.88%	98,300 $3.11 Million
Q2 2023 Aug 11, 2023	BUY	$34.58 - $46.03 $4.98 Million - $6.63 Million	144,100 Added 106.11%	279,900 $11.4 Million
Q1 2023 May 16, 2023	SELL	$33.3 - $44.82 $9,990 - $13,446	-300 Reduced 0.22%	135,800 $5.06 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $285,606 - $539,134	-8,600 Reduced 5.94%	136,100 $4.75 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $814,192 - $1.08 Million	15,100 Added 11.65%	144,700 $8.1 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.